Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA3B9T)

• Drug Name: AMG 673 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMA3B9T

Molecule-Related Drug Atlas

Drug(s) Targeting Myeloid cell surface antigen CD33 (CD33)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gemtuzumab ozogamicin	DMJ2O7B	Acute myeloid leukaemia	2A60	Approved	[3]
Vadastuximab talirine	DM9LH10	Acute myeloid leukaemia	2A60	Phase 3	[4]
Actimab-A	DMKBIPR	Acute myeloid leukaemia	2A60	Phase 2	[4]
BI-836858	DMUVMY9	Myelodysplastic syndrome	2A37	Phase 2	[5]
Actimab-MDS	DMP8EEX	Myelodysplastic syndrome	2A37	Phase 2	[6]
GTB-3550	DMK2RIB	Acute myelogenous leukaemia	2A41	Phase 1/2	[7]
SGN-CD33A	DMRC7PI	Acute myeloid leukaemia	2A60	Phase 1/2	[8]
CART33 cells	DM81JIT	Myeloid leukaemia	2B33.1	Phase 1/2	[9]
CD33-specific gene-engineered T cells	DMM35D2	Acute myeloid leukaemia	2A60	Phase 1/2	[10]
Anti-CD33 CAR-T cells	DM9NPF6	Myeloid leukaemia	2B33.1	Phase 1/2	[11]

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[12]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[13]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[14]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[15]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[16]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[17]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[18]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[19]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[20]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Myeloid cell surface antigen CD33 (CD33)	TTJVYO3	CD33_HUMAN	Inhibitor	[2]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[2]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of Amgen.
• [3] Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4:197-205.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 Jul;28(4):143-53.
• [6] Clinical pipeline report, company report or official report of Actinium Pharmaceuticals
• [7] Clinical pipeline report, company report or official report of GT Biopharma.
• [8] SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63.
• [9] ClinicalTrials.gov (NCT01864902) Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
• [10] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [11] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [12] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [13] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [14] Clinical pipeline report, company report or official report of Genmab.
• [15] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [16] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [17] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [18] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [19] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [20] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [21] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.